1-9 of 9
Daisy Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Gaurav Vadnerkar, Joan Clements, Mel Mann, Vainavika Reddy Gaddam, Chaitali Nag, Shiva Padhi, David Wei, Marcello Azolino, Kejal Jadhav, Daisy Yang, Andrea Damon, Islam Sadek
Journal: Blood
Blood (2024) 144 (Supplement 1): 5192.
https://doi.org/10.1182/blood-2024-199951
Published: 2024
Journal Articles

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Ehab L. Atallah, Moshe Y. Levy, Paul B. Koller, Koji Sasaki, Srinivas K Tantravahi, David Andorsky, Celesteann T Bremer, Joshua F Zeidner, Marlise R. Luskin, Reinhold Munker, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Michael J. Mauro, Jorge E. Cortes
Journal: Blood
Blood (2024) 144 (Supplement 1): 479.
https://doi.org/10.1182/blood-2024-200717
Published: 2024
Journal Articles

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Elias Jabbour, David Wei, Hongbo Yang, Kejal Jadhav, Wei Song, Yajin Zhao, Anran Shao, Samantha Tomicki, Daisy Yang, Andrea Damon, Islam Sadek, Vamsi K. Kota
Journal: Blood
Blood (2024) 144 (Supplement 1): 2434.
https://doi.org/10.1182/blood-2024-201831
Published: 2024
Journal Articles

ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs

Anchit Khanna, Hannah Small, Dhamend Lutchman, Rafael Erlich, Gabriel Marquez, Daisy Yang, Kejal Jadhav
Journal: Blood
Blood (2024) 144 (Supplement 1): 4527.
https://doi.org/10.1182/blood-2024-201022
Published: 2024
Journal Articles

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Ehab L. Atallah, Islam Sadek, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Daisy Yang, Remi Bellefleur, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2024) 144 (Supplement 1): 3812.
https://doi.org/10.1182/blood-2024-193201
Published: 2024
Journal Articles

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha C Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Kejal Jadhav, Courtney McDermott, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, Kathryn E. Flynn
Journal: Blood
Blood (2024) 144 (Supplement 1): 7913.
https://doi.org/10.1182/blood-2024-207213
Published: 2024
Journal Articles

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

Ehab L. Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul B. Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan GU, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 6389.
https://doi.org/10.1182/blood-2023-186974
Published: 2023
Journal Articles

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5190.
https://doi.org/10.1182/blood-2023-180789
Published: 2023
Journal Articles

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5098.
https://doi.org/10.1182/blood-2023-180772
Published: 2023